Preferred Name |
Alemtuzumab |
|
Synonyms |
ALEMTUZUMAB alemtuzumab Alemtuzumab Campath Campath-1H LDP-03 LDP03 Lemtrada MabCampath |
|
Definitions |
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04) |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1681 |
|
Accepted_Therapeutic_Use_For |
Chronic Lymphocytic Leukemia (CLL) |
|
ALT_DEFINITION |
A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells. |
|
CAS_Registry |
216503-57-0 |
|
code |
C1681 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
Contributing_Source |
CTRP FDA GDC HemOnc |
|
DEFINITION |
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04) |
|
Display_Name |
Alemtuzumab |
|
FDA_UNII_Code |
3A189DH42V |
|
FULL_SYN |
ALEMTUZUMAB alemtuzumab Alemtuzumab Campath Campath-1H LDP-03 LDP03 Lemtrada MabCampath |
|
Has_Target | ||
Is_Value_For_GDC_Property | ||
label |
Alemtuzumab |
|
Legacy Concept Name |
Alemtuzumab |
|
Maps_To |
Alemtuzumab |
|
NCI_Drug_Dictionary_ID |
37783 |
|
NSC Number |
715969 |
|
PDQ_Closed_Trial_Search_ID |
37783 |
|
PDQ_Open_Trial_Search_ID |
37783 |
|
Preferred_Name |
Alemtuzumab |
|
prefixIRI |
Thesaurus:C1681 |
|
Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
UMLS_CUI |
C0383429 |
|
subClassOf |